News
SAGE
13.58
-3.00%
-0.42
SAGE THERAPEUTICS INC <SAGE.O>: RBC CUTS TARGET PRICE TO $15 FROM $26
Reuters · 5h ago
SAGE Therapeutics’ Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold Rating
TipRanks · 5h ago
SAGE THERAPEUTICS INC <SAGE.O>: CANACCORD GENUITY CUTS TARGET PRICE TO $17 FROM $21
Reuters · 6h ago
Hold Rating on SAGE Therapeutics Amid Limited Revenue Prospects and Pipeline Uncertainty
TipRanks · 17h ago
Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and SAGE Therapeutics (SAGE)
TipRanks · 20h ago
SAGE Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
SAGE Therapeutics Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of $1.80 per share. Revenue rose 139.9% to $7.90 million from the same quarter last year. SAGE shares have fallen by 25.3% this quarter and 35.4% this year.
Reuters · 21h ago
SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024
Sage Therapeutics reported earnings per share of -$1.80 for the first quarter of 2024. The company reported revenue of $7.90 million. This was 39.61% better than the analyst estimate of $5.66 million for the quarter.
Investorplace · 21h ago
Needham Reiterates Hold on Sage Therapeutics
Benzinga · 1d ago
SAGE Therapeutics: Hold Rating Amidst Mixed Financial and Market Signals
TipRanks · 1d ago
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 1d ago
Sage Therapeutics Expects Cash & Equivalents Plus Funding To Support Its Operations Into 2026; Expects ZULRESSO Revenues To Continue To Decrease Over Time
The Company does not anticipate receipt of any additional milestone payments from collaborations in the remainder of 2024. The Company anticipates operating expenses will decrease in 2024 relative to 2023. With the availability of ZURZUVAE in the U.S. As an additional treatment for women with PPD, ZULRESSO revenues will continue to decrease.
Benzinga · 1d ago
Sage Therapeutics GAAP EPS of -$1.80 misses by $0.15, revenue of $7.9M beats by $2.71M
Seeking Alpha · 1d ago
Sage Therapeutics Q1 2024 GAAP EPS $(1.80) Misses $(1.65) Estimate, Sales $7.902M Beat $5.658M Estimate
Sage Therapeutics reported quarterly losses of $1.80 per share. The company also reported quarterly sales of $7.902 million. Sales beat the analyst consensus estimate of $5.658 million by 39.65%. The company missed the quarterly losses by 9.09 percent.
Benzinga · 1d ago
SAGE THERAPEUTICS INC - ANTICIPATES OPERATING EXPENSES WILL DECREASE IN 2024 RELATIVE TO 2023
Reuters · 1d ago
SAGE THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $717 MLN AS OF MARCH 31, 2024
Reuters · 1d ago
*Sage Therapeutics 1Q Loss $108.5M >SAGE
Dow Jones · 1d ago
*Sage Therapeutics Achieved 1Q $6.2M in ZURZUVAE (zuranolone) Collaboration Rev >SAGE
Dow Jones · 1d ago
*Sage Therapeutics 1Q Rev $7.9M >SAGE
Dow Jones · 1d ago
*Sage Therapeutics Cash, Cash Equivalents and Marketable Securities of $717 M as of March 31 >SAGE
Dow Jones · 1d ago
Press Release: Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress Achieved $6.2 million in ZURZUVAE collaboration revenue during the first quarter of 2024. More than 700 prescriptions shipped and delivered in the first quarters of 2024 for women with postpartum depression. Phase 2 PRECEDENT Study did not show statistically significant differences in Parkinson's Disease patients. Topline data expected for dalzanemdor in Huntington's Disease and Alzheimer's Disease in 2024.
Dow Jones · 1d ago
More
Webull provides a variety of real-time SAGE stock news. You can receive the latest news about Sage Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About SAGE
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.